Carla Vitorino – författare

Artificial Intelligence for Drug Product Lifecycle Applications explains the use of artificial intelligence (AI) in drug discovery and development paths, including the clinical and postapproval phases. This book gives methods for each of the drug development steps, from the fundamentals to postapproval drug product. AI is a synergistic assembly of enhanced optimization strategies with particular applications in pharmaceutical development and advanced tools for promoting cost-effectiveness throughout the drug lifecycle. Specifically, AI brings together the potential to improve drug approval rates, reduce development costs, get medications to patients faster, and help patients comply with their treatments.Accelerated pharmaceutical development and drug product approval rates will enable larger profits from patent-protected market exclusivity. This book offers the tools and knowledge to create the right AI strategy to extend the landscape of AI applications across the drug lifecycle. It is especially useful for pharmaceutical scientists, health care professionals, and regulatory scientists, as well as advanced students and postgraduates actively involved in pharmaceutical product and process development involving the use of artificial intelligence in drug delivery applications.Classifies AI methodologies and application examples into different categories representing the various steps of the drug development cycleCombines timely literature review with clear artworks to improve understandingExamines deep learning and machine learning in drug discovery

New Insights into Glioblastoma: Diagnosis, Therapeutics and Theranostics provides a compendium of recent diagnostic and therapeutic advances in GBM, encompassing a pipeline of compounds and (bio) nanotechnology strategies that have stood out with potential increased antitumoral activity and capability to cross the blood-brain barrier. Issues and challenges related to their translation into the clinical practice and their contribution to the increase in survival rates and well-being of patients are addressed. This is a valuable resource for graduate students, oncologists, cancer researchers and members of the biomedical field who need to learn more on recent developments on the management of glioblastoma.

The book is split in three parts: Diagnosis, focusing on biomarkers and techniques such PET/MRI, infrared thermography, and deep neural networks; Therapeutics, discussing new chemical entities, as natural products and repurposed drugs, and new formulation approaches, as nanotechnology-based and microRNA approaches; and Theranostics, explaining the role of omics, system-based approaches, and glioblastoma microenvironment.

Provides guidance towards recent advances of new chemical entities and delivery strategies targeted to glioblastoma Includes overviews to help readers apply information in their research Encompasses summarizing diagrams and real-world examples to facilitate comprehension and enhance the applicability of the content